Abstract Details

Title Impact of the Charlson Comorbidity Index on Mortality in Patients With Primary Central Nervous System Lymphoma

Topic Neuro-oncology

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-003

Objective In the present study, we aimed to identify the impact of the age-adjusted Charlson Comorbidity Index (CCI) on mortality in patients with primary central nervous system lymphoma (PCNSL).

Background PCNSL is a rare and aggressive form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, spinal cord, and cerebrospinal fluid. Identifying prognostic factors in PCNSL is imperative for patient stratification and management. CCI has been widely used for mortality prediction in solid cancer patients; however, there is limited evidence of its value in PCNSL.

Design/Methods This retrospective multicenter study analyzed patients over 18 years of age who were newly diagnosed with PCNSL between January 2007 to December 2022. The age-adjusted CCI was calculated at diagnosis to quantify comorbid burden. We used univariate and multivariate Cox regression models to identify predictors of mortality.

Results A total of 174 patients were screened, of whom 69 met the inclusion criteria for the study. Among the participants, 37 (53.6%) were female. The mean age at diagnosis was 62 years. The cohort was predominantly Caucasian (95.65%). The mean age-adjusted Charlson Comorbidity Index (CCI) score was 5.72. The median survival time for the cohort was 4.12 years. In the univariate analysis, a higher age-adjusted CCI score was significantly associated with increased mortality (HR = 1.33; 95% CI: 1.20–1.48; p < 0.0001). In the multivariate analysis, both elevated age-adjusted CCI scores and Eastern Cooperative Oncology Group Performance Status scores of 3–4 were independently associated with higher mortality. Higher methotrexate dose was associated with reduced mortality in univariate but not multivariate analysis. Delayed presentation from symptom onset was also linked to increased mortality in univariate analysis but lost significance in the multivariate model.

Conclusions CCI is a significant prognostic factor in patients with PCNSL, with higher scores at diagnosis corresponding to an increased risk of mortality.

Authors/Disclosures
Joyce A. Jimenez Zambrano, MD PRESENTER	Dr. Jimenez Zambrano has nothing to disclose.
Nishita Gaba	Miss Gaba has nothing to disclose.
Ramiz Kirmani, MD (University of North Dakota)	Dr. Kirmani has nothing to disclose.
Aarabhi Gurumoorthy, BDS	Dr. Gurumoorthy has nothing to disclose.
Kayla Geyer	Mrs. Geyer has nothing to disclose.
Anu Gaba, MD	Dr. Gaba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Curio Science. Dr. Gaba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Omni Oncology.

��ɫ��

��ɫ��